TapImmune Inc (TPIV)

4.00
NASDAQ : Health Care
Prev Close 3.71
Day Low/High 3.62 / 4.00
52 Wk Low/High 3.95 / 11.64
Avg Volume 28.50K
Exchange NASDAQ
Shares Outstanding 8.47M
Market Cap 31.43M
EPS -0.40
P/E Ratio 4.67
Div & Yield N.A. (N.A)

Latest News

TapImmune To Provide First Quarter 2017 Business Update Conference Call And Webcast

Company to Provide Corporate and Clinical Overview on Wednesday, May 31, 2017, 4:30pm ET

Richard Kenney, MD, FACP, Joins TapImmune To Lead The Clinical Development Program

Seasoned Vaccinologist with extensive experience in Immunotherapy Clinical Trials

TapImmune Provides Year End 2016 Corporate And Clinical Update

Conference Call and Live Audio Webcast Scheduled for Today at 4:30 pm ET

TapImmune Announces Fully Funded Phase 2 Clinical Study Of HER2-Targeted Vaccine In Early Breast Cancer

Collaborators at Mayo Clinic Secure New $3.7 Million Grant from U.S. Department of Defense

TapImmune To Host Inaugural Quarterly Business Update Conference Call And Webcast

Company to Provide Corporate and Clinical Overview on Tuesday, March 14, 2017, 4:30pm ET

TapImmune Advances TPIV 200 Phase 2 Triple-Negative Breast Cancer Trial After Favorable DSMB Safety Review

Independent Review Board Confirms Interim Safety Profile of TPIV 200

TapImmune Expands Intellectual Property On PolyStartâ„¢ Platform For Use In Next-Generation T-Cell Vaccines

Receives Notice of Allowance for New Patent Covering Expression of Specific Antigens

TapImmune Announces Progress In Its Phase 2 Ovarian Cancer Clinical Trial

TapImmune Announces Progress In Its Phase 2 Ovarian Cancer Clinical Trial

Trial in Collaboration with Memorial Sloan Kettering Cancer Center Completes First Safety Cohort Successfully

TapImmune Launches Phase 2 Ovarian Cancer Trial In Platinum-Sensitive Patients

TapImmune Launches Phase 2 Ovarian Cancer Trial In Platinum-Sensitive Patients

Company-Sponsored Ovarian Cancer Trial Has FDA Fast Track Designation

TapImmune: Year End 2016 Update

TapImmune: Year End 2016 Update

TapImmune Announces Commercialization Pathway For Its HER2neu Vaccine

TapImmune Announces Commercialization Pathway For Its HER2neu Vaccine

Initiation of Company-Sponsored Phase 2 Clinical Trials will start early 2017

MicroCap Review Magazine Fall 2016 Issue Now Available

MicroCap Review Magazine Fall 2016 Issue Now Available

The Digital Issue of the Fall 2016 MicroCap Review Magazine, The Official Magazine for the MicroCap Stock Market, can be read on www.StockNewsNow.com

TapImmune Appoints Michael J. Loiacono As Chief Financial Officer

TapImmune Appoints Michael J. Loiacono As Chief Financial Officer

Accomplished Financial Director & CFO of Public Companies

TapImmune Doses First Patient In Its Phase 2 Triple Negative Breast Cancer Trial For Cancer Vaccine TPIV 200

TapImmune Doses First Patient In Its Phase 2 Triple Negative Breast Cancer Trial For Cancer Vaccine TPIV 200

Cancer vaccine TPIV 200 to be evaluated in four Phase 2 trials in 2016

TapImmune Announces Finalization Of License Agreement With Mayo Clinic To Commercialize A HER2neu Vaccine

TapImmune Announces Finalization Of License Agreement With Mayo Clinic To Commercialize A HER2neu Vaccine

Agreement Will Allow for the Transfer of IND from Mayo to TapImmune and the Initiation of Company-Sponsored Phase 2 Clinical Trials